Sanifit

Sanifit is a clinical stage company that develops SNF472 a compound for the treatment of End Stage Renal Disease (ESRD) and calciphylaxis patients undergoing haemodialysis and suffer from severe cardiovascular complications related to calcification of their blood vessels. Sanfit’s lead program is focused on a registration trajectory in Calciphylaxis by its pivotal CALCIPHYX phase III trial.